Wells Fargo & Company Issues Pessimistic Forecast for Monte Rosa Therapeutics (NASDAQ:GLUE) Stock Price

Monte Rosa Therapeutics (NASDAQ:GLUE) had its price target lowered by investment analysts at Wells Fargo & Company from $30.00 to $29.00 in a report released on Wednesday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Wells Fargo & Company‘s target price points to a potential upside of 80.57% from the stock’s current price.

GLUE has been the topic of a number of other reports. Weiss Ratings reissued a “sell (d)” rating on shares of Monte Rosa Therapeutics in a report on Monday, December 29th. Zacks Research cut Monte Rosa Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 4th. Guggenheim dropped their target price on Monte Rosa Therapeutics from $34.00 to $30.00 and set a “buy” rating on the stock in a research report on Wednesday. Wedbush reissued an “outperform” rating and set a $37.00 price target on shares of Monte Rosa Therapeutics in a research report on Wednesday, January 7th. Finally, TD Cowen restated a “buy” rating on shares of Monte Rosa Therapeutics in a research note on Wednesday, January 7th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Monte Rosa Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $32.80.

Monte Rosa Therapeutics Trading Up 1.9%

NASDAQ GLUE opened at $16.06 on Wednesday. The firm’s fifty day simple moving average is $19.80 and its two-hundred day simple moving average is $14.76. The firm has a market capitalization of $1.29 billion, a P/E ratio of -34.91 and a beta of 1.63. Monte Rosa Therapeutics has a 12-month low of $3.50 and a 12-month high of $25.77.

Monte Rosa Therapeutics (NASDAQ:GLUE) last announced its earnings results on Tuesday, March 17th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by ($0.10). The business had revenue of $2.78 million for the quarter, compared to analyst estimates of $17.09 million. Monte Rosa Therapeutics had a negative net margin of 31.23% and a negative return on equity of 15.12%. As a group, sell-side analysts predict that Monte Rosa Therapeutics will post -1.49 earnings per share for the current fiscal year.

Insider Transactions at Monte Rosa Therapeutics

In related news, insider Edmund Dunn sold 25,164 shares of the company’s stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $18.10, for a total transaction of $455,468.40. Following the completion of the transaction, the insider owned 22,693 shares in the company, valued at $410,743.30. This represents a 52.58% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Markus Warmuth sold 5,466 shares of the firm’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $17.92, for a total transaction of $97,950.72. Following the completion of the transaction, the chief executive officer directly owned 613,471 shares in the company, valued at $10,993,400.32. This represents a 0.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 36,771 shares of company stock valued at $693,692 in the last three months. Corporate insiders own 6.90% of the company’s stock.

Institutional Trading of Monte Rosa Therapeutics

Large investors have recently made changes to their positions in the company. Campbell & CO Investment Adviser LLC acquired a new stake in shares of Monte Rosa Therapeutics in the third quarter valued at about $379,000. Squarepoint Ops LLC purchased a new position in shares of Monte Rosa Therapeutics during the 2nd quarter worth $803,000. Allspring Global Investments Holdings LLC acquired a new position in shares of Monte Rosa Therapeutics during the 3rd quarter valued at about $182,000. Los Angeles Capital Management LLC purchased a new stake in shares of Monte Rosa Therapeutics in the second quarter valued at about $89,000. Finally, Hillsdale Investment Management Inc. purchased a new stake in shares of Monte Rosa Therapeutics in the second quarter valued at about $271,000. 79.96% of the stock is currently owned by hedge funds and other institutional investors.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.